DSIP
Also known as: Delta Sleep-Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Neuropeptide that promotes deep sleep and reduces sleep latency through endocrine and neurotransmitter modulation.
Evidence
Emerging
FDA status
Not FDA-approved
Source
Naturally occurring neuropeptide
Overview
Neuropeptide that promotes deep sleep and reduces sleep latency through endocrine and neurotransmitter modulation.
Mechanism of Action
Stimulates somatoliberin (GHRH) while inhibiting somatostatin for SWS promotion, modulates NMDA and α1-adrenergic receptors, influences GABA release, reduces corticotropin and stress hormones (~30% reduction), normalizes sleep-wake cycle signaling.
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- Enhances slow-wave sleep (deep sleep)
- Reduces sleep onset latency
- Improves sleep efficiency
- Reduces stress hormones
- Sleep patterns
- Withdrawal symptoms (small early studies)
Researched for
Research topics, not approved uses.
How Gabriel approaches peptides
Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. DSIP isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.
Research & Evidence
Limited human trials, preclinical studies
Small human studies in the 1980s and 1990s gave mixed results for insomnia, and research largely stopped. It is not FDA-approved.
Safety Information
Potential Side Effects
- •Daytime drowsiness (rare)
- •Headache
Contraindications
- Pregnancy
- Breastfeeding
Interactions
- ⚠May potentiate sedatives